Mastery EAQ Ch. 34

A  Decreased pain

B  Strong contractions

C  Midline fundus

D  Softened cervix

A  Ovarian failure

B  Abnormal vaginal bleeding

C  Pulmonary embolism

D  Renal failure

A  Blurred vision, Bradycardia, Increased diuresis

B  Hirsutism, Dizziness,, Increased diuresis

C  Hirsutism, Bradycardia, Increased diuresis

D  Anxiety, Dizziness, Blurred vision

A  Until three throat cultures have been negative for the pathogen

B  For at least 1 month after starting the antibiotic

C  For at least 6 weeks, starting at the end of the antibiotic regimen

D  During the entire period the patient is taking the antibiotic

A  Methylergonovine

B  Alendronate

C  Estradiol

D  Megestrol

A  Epinephrine

B  Protamine sulfate

C  Calcium gluconate

D  Atropine

A  Decrease the drug dose immediately.

B  Obtain a prescription for terbutaline.

C  Obtain a prescription for indomethacin.

D  Request a prescription to give calcium gluconate.

A  Immediately discontinue intravenous (IV) fluids.

B  Instruct the patient to bear down and push.

C  Administer phentolamine mesylate.

D  Place the patient on her left side.

A  Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B  Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

C  Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

D  Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

A  Nausea and vomiting

B  Hypertension

C  Pelvic inflammatory disease

D  Uterine atony

A  Temperature

B  Uterine contractions

C  Blood glucose

D  Blood pressure

A  Radiographic confirmation of cephalopelvic disproportion

B  Ineffective contractions in a full-term pregnancy

C  Vaginal bleeding at 38 weeks’ gestation

D  Absence of cervical ripening at 42 weeks’ gestation

A  Low fluid intake

B  Current tricyclic antidepressant use

C  Use of herbal supplements

D  Cigarette use

A  The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

B  Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

C  Uterine hyperactivity, Fetal heart rate, Complete blood cell count

D  Fetal movement, Uterine hyperactivity, Complete blood cell count

A  Tamoxifen

B  Denosumab

C  Ibandronate

D  Calcitonin

A  Persuade the patient to start the therapy.

B  Inform the patient about the benefits and risks of the therapy.

C  Advise the patient to engage in quiet activities.

D  Ask the patient to include soy in her diet.

A  “You may need to stop smoking during the therapy.”

B  “The treatment is likely to cause endometrial cancer.”

C  “The therapy may cause thromboembolic events.”

D  “The treatment should be started as soon as possible.”

A  Terbutaline

B  Magnesium sulfate

C  Bed rest and hydration

D  Ritodrine

A  Hypertension

B  Anticonvulsant therapy

C  Diabetes

D  Antibiotic therapy

A  Medroxyprogesterone

B  Norethindrone and ethinyl estradiol

C  Male condom with spermicidal jelly

D  Cervical cap with spermicidal jelly

A  Joint pain

B  Current smoker

C  Allergy to salmon

D  Breast cancer

A  “Discontinue the calcium supplement.”

B  “Space the medications 1 to 2 hours apart.”

C  “Obtain a prescription for increasing the bisphosphonate dose.”

D  “Replace the bisphosphonate with calcitonin.”

A  “Have a yearly mammogram.”

B  “Perform weight-bearing exercise.”

C  “Have tests for serum cholesterol.”

D  “Report missed menstrual periods.”

A  “High progesterone levels inhibit the release of luteinizing hormone.”

B  “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”

C  “Estrogen levels inhibit the release of follicle-stimulating hormone.”

D  “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”

A  “I have not experienced any uterine bleeding.”

B  “I have seen a great improvement in my sexual desire.”

C  “I no longer experience hot flashes.”

D  “I am no longer experiencing painful intercourse.”

A  Metformin

B  Amoxicillin

C  Ferritin

D  Levothyroxine

A  Promotes bone absorption of calcium

B  Stimulates estrogen receptors on the bone to increase bone density

C  Inhibits osteoclast-mediated bone reabsorption

D  Contains estrogen, which stimulates bone reabsorption

A  Multivitamin, Atenolol

B  Levothyroxine, Multivitamin

C  Atenolol, Levothyroxine

D  Warfarin, Cholestyramine

A  “I will take the medication on an empty stomach and not lie down for 30 minutes.”

B  “I need to decrease my intake of dairy products to prevent hypercalcemia.”

C  “I need to take this medication with food to prevent damage to my esophagus.”

D  “This medication will help relieve the bone pain I have from my osteoporosis.”

A  Hot flashes, Vertigo, Loss of appetite

B  Hot flashes, Loss of appetite, Joint pain

C  Chest pain, Hot flashes, Loss of appetite

D  Vertigo, Joint pain, Chest pain

A  To induce cervical ripening

B  To treat gestational hypertension

C  To terminate pregnancy

D  To treat pelvic inflammatory disease

A  Smoking heavily every day

B  Sedentary lifestyle

C  Increased body mass index (BMI)

D  Consumption of saturated fats

A  Monotherapy with a progestin increases breast cancer risk.

B  Estrogen monotherapy increases the risk of breast cancer.

C  Estradiol with progestin increases the risk of endometrial cancer.

D  Unopposed estrogen increases the risk of endometrial cancer.

A  Clomiphene

B  Terbutaline

C  Prostaglandin E

D  Oxytocin

A  Megestrol

B  Medroxyprogesterone

C  Estropipate

D  Estrone

A  Hot flashes

B  Brown discoloration of face

C  Loss of hair

D  Yellow undertone to the skin

A  Suggest the patient take aluminum hydroxide with the medication.

B  Assess pulse oximetry continuously.

C  Administer acetaminophen as needed.

D  Monitor the patient’s blood pressure frequently.

A  Oxytocin

B  Dinoprostone

C  Clomiphene

D  Indomethacin

A  Progesterone

B  Clomiphene

C  Choriogonadotropin alfa

D  Ethinyl estradiol

A  Uterine bleeding

B  Deep vein thrombosis

C  Weight loss

D  Dysmenorrhea

A  “The progestin in the regimen will help prevent ovarian cancer.”

B  “Endometrial cancer risk can be reduced by adding progestin.”

C  “The progestin in the regimen will help prevent breast cancer.”

D  “Vaginal cancer is prevented by adding progestin to the regimen.”

A  Elevated progesterone levels inhibiting the release of the luteinizing hormone

B  Inhibition of the release of gonadotropins

C  Interference with the proliferation of the fertilized ovum

D  Diminished endometrial tissue proliferation

A  Antidiuretic hormone

B  Follicle-stimulating hormone

C  Adrenocorticotropic hormone

D  Luteinizing hormone

A  Thrombophlebitis

B  Weight gain

C  Hypertension

D  Dysmenorrhea

A  Higher-pitched voice

B  Weight loss

C  Nausea

D  Dry skin

A  Premature labor

B  Accelerated labor

C  Postpartum hemorrhage

D  Termination of pregnancy

A  Medroxyprogesterone

B  Megestrol

C  Esterified estrogens

D  Alendronate

A  Phase 3

B  Phase 1

C  Phase 4

D  Phase 2

A  Monophasic

B  Biphasic

C  Triphasic

D  Extended-cycle

A  Interstitial cell-stimulating hormone

B  Follicle-stimulating hormone (FSH)

C  Luteinizing hormone (LH)

D  Luteotropic hormone

A  Methylergonovine

B  Indomethacin

C  Medroxyprogesterone acetate

D  Megestrol

A  Methylergonovine

B  Terbutaline

C  Oxytocin

D  Magnesium sulfate

A  Raloxifene

B  Clomiphene

C  Megestrol

D  Methylergonovine

A  Day 3

B  Day 14

C  Day 7

D  Day 21

A  Antidiuretic hormone

B  Luteinizing hormone (LH)

C  Follicle-stimulating hormone (FSH)

D  Adrenocorticotropic hormone

A  The fetal heart rate is stable.

B  The patient is ready for delivery.

C  The contractions can be fatal to the patient.

D  The patient’s blood pressure is stable.

A  Current use of medications for depression

B  Current smoking status

C  Presence of abnormal uterine bleeding

D  Compliance with the fertility drugs

A  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

C  Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

D  Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events